황반부종에 대한 베바시주맙 유리체강내 주사의 효과

• 영문명: The Efficacy of Intravitreal Bevacizumab in the Treatment of Macular Edema
• 발행기관: 대한안과학회
• 저자명: 문선경 이수영 이정희,Sun-Kyung Moon, MD, Soo Young Lee, MD, PhD, Jeong-Hee Lee, MD, PhD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume50,number8, 1232~1236쪽, 전체 5쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2009.08.15

영문 초록

Purpose: To investigate the efficacy in best corrected visual acuity (BCVA) and central macularthickness after intravitreal bevacizumab injection in patients with macular edema. Methods: Patients with macular edema due to branch retinal vein occlusion, central retinal vein occlusion, and diabetic retinopathy received intravitreal injection of bevacizumab (2.5 mg/0.1cc). Complete ophthalmic examinations including best corrected visual acuity and optical coherence tomography (OCT) were performed at baseline and follow-up visits for 6 months. Results: In macular edema secondary to branch retinal vein occlusion, the mean BCVA improved from logMAR 0.62±0.30 at baseline to logMAR 0.43±0.37 at 1 month, 0.34±0.40 at 3 months and 0.38±0.37 at 6 months (p<0.05). The mean central macular thickness decreased from 451.2±118.9 μm at baseline to 280.3±124.6 μm at 1 month, 345.8±157.1 μm at 3 months and 312.9±174.4 μm at 6 months (p<0.05). In macular edema secondary to central retinal vein occlusion and diabetic retinopathy, visual improvement and macular thickness reduction were not statistically significant. Conclusions: Intravitreal bevacizumab injection appears to be more effective for macular edema due to branch retinal vein occlusion than macular edema secondary to central retinal vein occlusion and diabetic retinopathy.

키워드

Bavacizumab, Diabetic retinopathy, Macular edema, Retinal vein occlusion